Outsourcing STREAM

  1. How MilliporeSigma Promotes Quality And Risk Reduction 10/20/2021

    Learn how MilliporeSigma’s new facility was built with quality and risk reduction at the top of mind and its experts have the experience to support large-scale programs through commercialization.

  2. Explore The M Lab Collaboration Center In Burlington MA 9/19/2022

    Our global network of scientific experts, innovative technologies, and non-GMP facilities, empower drug developers of all sizes to achieve manufacturing excellence and innovation through collaborative exploration and learning. Explore 1 of our 8 global facilities today.

  3. Level Up With Product Characterization 3/12/2021

    In the race to bring a new biotherapeutic to market, unexpected obstacles can slow you down or even knock you back a few steps. But with the right information at the right time, and an experienced partner to provide scientific, regulatory, and bioprocessing guidance and support, you can find a smoother, faster path to the finish line.

  4. Increasing The Reach Of Cell And Gene Therapies 4/29/2021

    The cell and gene therapy industry is rapidly evolving from the perspective of “can we commercialize this class of therapeutics?” to “how do we reach patients who need these therapies?”. However, the promise of these biologics can only be realized if the industry approaches manufacturing parity with monoclonal antibodies. A mixture of innovation and brute-force streamlining is needed to create viable cell and gene therapy templates. In this video, we discuss how upstream process optimization is ripe for innovative approaches.

  5. Commercial Readiness with Orca Bio's Dan Kirby 9/14/2023

    Orca Bio's Dan Kirby has played a hand in prepping more than a few approved biologic therapeutic candidates for commercialization. Equally important, he knows firsthand what makes or breaks post-approval commercial efforts, having played virtually every role there is to play in drug sales and marketing.

  6. Protecting Biopharma Manufacturing Supply Chains 2/5/2026

    In this final segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” panelists Adam Golin, Jon Lindbloom, and James Sapirstein share their advice and best practices for sourcing suppliers and staying agile during periods of change in the industry.

  7. Thermo Fisher Scientific North America Single-Use Technologies Capacity Expansion 3/2/2021

    Thermo Fisher Scientific is expanding our single-use manufacturing network globally. Some of the largest investments are taking place at our existing Logan, Utah, and Millersburg, Pennsylvania, sites. We are adding space for clean rooms for the manufacturing and assembly of Thermo Scientific BioProcess Containers and fluid transfer assemblies, investing in 2D and 3D chamber manufacturing equipment, and harmonizing our quality systems and processes.

  8. How Will U.S. Tariffs And The BIOSECURE Act Impact Global Biopharma Markets? 2/5/2026

    In this segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” panelists explain how tariffs imposed by the U.S. are putting competitive pressure on companies to reduce COGs. They also discuss the short- to long-term impact of efforts to onshore biomanufacturing.

  9. Factors Which Impact mAb Process Scale-Up 9/7/2021

    Thinking about your mAb scale-up processes early on can help avoid common pitfalls. Cytiva’s Fast Trak scientists discuss factors that can influence a successful scale-up outcome.

  10. MilliporeSigma Capacity Update October 2025: ADC 7/28/2025

    MilliporeSigma and Simtra's streamlined collaboration encompasses every stage, including bioconjugation, linker and payload supplies, formulation development, and final fill/finish of drug substance.